HomeNewsBusinessMarketsNifty breaks 6250; BHEL falls 2%, pharma stocks weak

Nifty breaks 6250; BHEL falls 2%, pharma stocks weak

Ukraine's new PM has accused Russia of declaring war on the country. This is after Russia moved troops to three bases in Crimea on Sunday. The G7 has condemned Russia’s intrusion into Ukraine and canceled preparations for the G8 summit that had been scheduled to take place in Sochi in June.

March 03, 2014 / 14:13 IST
Story continues below Advertisement

Moneycontrol Bureau Live Market Commentary

2:00 Should Sebi intervene?Just as the dust was beginning to settle on the Fresenius Kabi delisting controversy, another MNC's action has reignited the debate on whether the delisting guidelines are being gamed by promoters looking for a cheap exit.

Story continues below Advertisement

AstraZeneca Pharma today said that its board would be meeting on Wednesday to consider a proposal to delist the company. The foreign parent holds 75 percent in the company, having reduced stake from 90 percent in May last year through an offer for sale (OFS) to institutional investors at Rs 620 per share. AstraZeneca had taken the OFS route to comply with the Sebi rule mandating listed companies to maintain minimum 25 percent public shareholding.

To delist, the foreign parent now needs to buy an additional 15 percent from investors. Under current rules, promoters with less than 90 percent stake looking to delist, have to make an offer for minimum 50 percent of the outstanding equity and take their stake to 90 percent. For promoters holding 90 percent and above, the offer has to be for a minimum of 50 percent of the outstanding equity.